Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
PharmaHangzhou, China, China · Est. 1997
Chia Tai Tianqing Pharmaceutical Group is a Chinese pharmaceutical company focused on researching, developing, and commercializing innovative drugs for oncology, cardiovascular, and metabolic diseases.
15
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
15
Indications↗
Distinct diseases across all programs
327
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
15 drugs in development
Phase 39
Phase 23
Phase 14
By Therapeutic Area
top 5
Oncology
741%
Hematology
318%
Immunology
212%
Respiratory
16%
Infectious Disease
16%
R&D Momentum
81/100
Pipeline Velocity
55/100
Trial Completion Rate
71/100
Pipeline Concentration
25/100
Pipeline Freshness
49/100
Strategic Signals
- ↗Active in Immunology but thin pipeline — potential licensing opportunity
Activity
Key Events
Oct 21, 2026TrialPhase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3126 in Subjects With Breast Cancer
Oct 17, 2026TrialPhase 1b Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention
Oct 3, 2026TrialA Randomized, Double-Blind, Placebo-Controlled Phase III Trial With an Open-Label Extension to Evaluate the Efficacy and Safety of TQA3605 Tablets in Chronic Hepatitis B Virus-Infected Patients With Low-Level Viremia or Suboptimal Response After at Least 12 Months of NAs Therapy
Sep 29, 2026TrialEvaluation of Safety Profile in a Cohort Study of Inhaled TQC3721 Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Sep 26, 2026TrialA Multicenter, Randomized, Open, Parallel Controlled Phase III Study Comparing the Efficacy and Safety of Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
Sep 25, 2026TrialA Multicenter, Single-Arm Study to Evaluate the Effectiveness and Safety of Tabellvi® (Adalimumab) in Chinese Adult Subjects With Moderate to Severe Active Crohn's Disease in the Real-World Setting
Sep 16, 2026TrialA Phase Ib/II Clinical Trial Evaluating the Safety and Efficacy of TQB6411 Injection in Participant s With Recurrent or Metastatic Esophageal Cancer Who Have Failed Prior PD-1/PD-L1 Inhibitor Plus Platinum-Based Chemotherapy
Sep 12, 2026TrialEvaluate TQ-A3334 Tablets Combined Nucleoside (Acid) Analogs in the Initial Treatment/Chronic Hepatitis B Virus (HBV) Infection Subjects of Chronic HBV Infection
4 more events
Sep 11, 2026TrialA Randomized, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Sep 11, 2026TrialPost-marketing Case Registration Study on the Safety and Efficacy of Taibowei® Adalimumab Injection for Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
Sep 9, 2026TrialA Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of TQB6411 for Injection in Patients With Advanced Lung Cancer
Sep 5, 2026TrialRandomized, Double-blind, Parallel-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Polymyxin E2 Mesylate Intravenous Infusion Combined With Nebulized Inhalation in the Treatment of Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia Caused by Carbapenem-resistant Gram-negative Bacteria
Details
Company Info
Therapeutic Focus
OncologyCardiovascular diseaseDiabetes
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Infectious Disease
Oncology
Hematology
Immunology
Chronic Graft Versus Host Disease
RovadicitinibPhase 3
TQ05105Phase 2
Infectious Disease
Chronic Hepatitis
TQA3810Phase 2
Oncology
Respiratory
Unknown / Other
Showing 15 of 17 programs
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)